Company Profile
< < Back  
Company Name : MedReleaf Corp.
Address : P.O. Box 3040, Markham Industrial Park, Markham, Ontario, Canada L3R 6G3
Phone : (289) 317-1004
Fax :
President : Eitan Popper
Web Site :
Email :
Date of Formation : February 28, 2013

Management & Directors :
Directors and executive officers upon Closing

Neil Closner - Chief Executive Officer and Director
Lloyd M. Segal - Director, Chairman
Deborah Rosati - Director
Norma Beauchamp - Director
Ronald Funk - Director
Igor Gimelshtein - Chief Financial Officer and Corporate Secretary
Eitan Popper - President
Angelo Fefekos - Vice-President, Clinical Affairs and Quality Compliance
Darren Karasiuk - Vice-President, Strategy
Ivan Latysh - Vice-President, Information Technology

Business Description :
MedReleaf Corp. is a Licensed Producer of cannabis-based pharmaceutical products based in Markham, Ontario. The Company is licensed by Health Canada pursuant to the ACMPR to, among other things, produce at its Markham Facility an aggregate of up to 6,000 kilograms of dried cannabis and up to 1,760 kilograms of cannabis oil, and to sell and distribute within Canada an aggregate of up to 5,000 kilograms of dried cannabis, up to 1,319 kilograms of bottled cannabis oil, and up to 440 kilograms of encapsulated cannabis oil produced at its Markham Facility, pursuant to the Markham Commercial Licence. The current term of the Markham Commercial Licence expires on August 15, 2018.

The Company also obtained a cultivation licence from Health Canada pursuant to the ACMPR in respect of its Bradford Facility, permitting the cultivation of up to 100 kilograms of dried cannabis, of which it may sell or provide up to three kilograms, solely for the purpose of analytical testing. The current term of the Bradford Cultivation Licence expires on April 11, 2018. While the production capacity of the completed first phase of the Bradford Facility exceeds the maximum production volume permitted by the Bradford Cultivation Licence, the licence's production limitations and sales restrictions are typical for an initial licence issued by Health Canada to a Licensed Producer. Accordingly, as it has done in the past from time to time in respect of the Markham Commercial Licence, management intends to apply in due course for an amendment to the Bradford Cultivation Licence in order to increase the maximum production volume to a level in line with the Bradford Facility's production capacity, and to permit the sale of cannabis-based pharmaceutical products.

MedReleaf cultivates and produces its cannabis-based pharmaceutical products for direct sales to its patients from the Markham Facility across Canada. The Company interacts with its patients via its e-commerce platform as well as by phone and email correspondence directed to its patient-care team. Currently, the Company sells dried cannabis, cannabis oils and cannabis oil capsules to its patients from its Markham Facility. MedReleaf's sales are supported by a variety of initiatives, including health conference sponsorships, as well as through its cannabis education and outreach team of employees. The Company expects both its portfolio of products and the jurisdictions outside of Canada in which it operates to expand as local laws allow, resources permit, and where market research indicates opportunity.

Company Financials :
Fiscal Year-End :March 31
Financials :Revenue for the year ended March 31, 2016 - $19,301,801
Net income for the year ended March 31, 2016 - $3,370,638

Revenue for the year ended March 31, 2015 - $2,998,736
Net loss for the year ended March 31, 2015 - $(723,504)

Disclaimer: A preliminary prospectus, and any amendments thereto, relating to these securities has been filed with securities commissions in certain provinces, but has not yet become final for the purpose of distribution to the public. This web page shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale or any acceptance of an offer to buy these securities prior to the time a receipt for the final prospectus or other authorization is obtained from the securities commission.

Search by Symbol       Canada   US